Teri Klein | Academic Influence

Teri Klein's AcademicInfluence.com Rankings

Teri Klein

Computer Science

#5174

World Rank

#5468

Historical Rank

Machine Learning

#2366

World Rank

#2395

Historical Rank

Artificial Intelligence

#2650

World Rank

#2691

Historical Rank

Database

#3949

World Rank

#4107

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Teri Klein's Degrees

PhD Computer Science Stanford University
Masters Computer Science Stanford University
Bachelors Computer Science Stanford University

Similar Degrees You Can Earn

Why Is Teri Klein Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Teri E. Klein is an American professor of Biomedical Data Science and Medicine at Stanford University. She is known for her work on pharmacogenomics and computational biology. Education Klein has a B.A. from the University of California, Santa Cruz and a Ph.D. from the University of California, San Francisco . In 2000 she started a position at Stanford University where, as of 2022, she holds the position of professor .

(See a Problem?)

Teri Klein's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Estimation of the warfarin dose with clinical and pharmacogenetic data. (2009) (1522)
Pharmacogenomics Knowledge for Personalized Medicine (2012) (1504)
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics (2016) (1319)
Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes (2012) (1128)
Doxorubicin pathways: pharmacodynamics and adverse effects (2011) (1073)
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network (2011) (845)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update (2013) (837)
Clinical assessment incorporating a personal genome (2010) (692)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors (2015) (690)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing (2011) (613)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing (2011) (607)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update (2014) (560)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing (2015) (430)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy (2011) (429)
Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update (2017) (423)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update (2017) (414)
PharmGKB: the Pharmacogenetics Knowledge Base (2002) (397)
Integrating genotype and phenotype information: an overview of the PharmGKB project (2001) (383)
Metformin pathways: pharmacokinetics and pharmacodynamics (2012) (365)
Clinical interpretation and implications of whole-genome sequencing. (2014) (365)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype (2012) (362)
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. (2015) (357)
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update (2014) (353)
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) (2016) (353)
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). (2011) (351)
Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process (2014) (346)
Prediction of CYP2D6 phenotype from genotype across world populations (2016) (344)
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. (2010) (341)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (2018) (335)
Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update (2019) (331)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update (2013) (314)
The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy (2012) (311)
The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database (2017) (298)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing (2013) (297)
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group (2019) (256)
The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response (2007) (242)
PharmGKB: the Pharmacogenomics Knowledge Base. (2013) (237)
ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG) (2021) (235)
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study (2013) (232)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy (2017) (232)
Challenges in the clinical application of whole-genome sequencing (2010) (231)
Valproic acid pathway: pharmacokinetics and pharmacodynamics (2013) (230)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (2018) (213)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing (2014) (206)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen‐B Genotype and Allopurinol Dosing (2013) (196)
PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses (2015) (186)
Cytochrome P450 2C9-CYP2C9. (2010) (186)
From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. (2011) (184)
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing (2012) (183)
PharmGKB summary: cyclosporine and tacrolimus pathways (2013) (180)
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations (2013) (176)
PharmGKB: A worldwide resource for pharmacogenomic information (2018) (169)
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (2018) (167)
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real‐World Implementation (2013) (166)
Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group (2018) (162)
An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine (2021) (156)
Clopidogrel pathway. (2010) (153)
Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence (2011) (149)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing (2016) (145)
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron (2017) (142)
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19 (2012) (140)
The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later (2020) (134)
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti‐Inflammatory Drugs (2020) (134)
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8 (2012) (133)
PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base (2004) (130)
Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting (2016) (129)
Cytochrome P450 2D6. (2009) (124)
Celecoxib pathways: pharmacokinetics and pharmacodynamics. (2012) (122)
PharmGKB summary: very important pharmacogene information for CYP3A5. (2012) (121)
Pharmacogenomics and bioinformatics: PharmGKB. (2010) (118)
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy (2021) (118)
PharmGKB summary: methotrexate pathway. (2011) (117)
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems (2017) (115)
Challenges for biomedical informatics and pharmacogenomics. (2002) (115)
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA‐B) genotype and allopurinol dosing: 2015 update (2016) (114)
The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge (2007) (112)
The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response (2015) (111)
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing: 2014 Update (2014) (111)
Implementing Personalized Medicine: Development of a Cost‐Effective Customized Pharmacogenetics Genotyping Array (2012) (110)
PharmVar GeneFocus: CYP2D6 (2020) (109)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (2020) (107)
Codeine and morphine pathway. (2009) (104)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype (2014) (103)
Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy (2019) (102)
Nomenclature for alleles of the thiopurine methyltransferase gene (2013) (102)
PharmGKB summary: ibuprofen pathways (2015) (99)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy (2019) (95)
PharmGKB: Understanding the Effects of Individual Genetic Variants (2008) (94)
Pharmacogenetics of warfarin: challenges and opportunities (2013) (94)
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG) (2021) (94)
Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects (2018) (93)
VKORC1 pharmacogenomics summary. (2010) (93)
The Evolution of PharmVar (2018) (92)
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. (2014) (91)
PharmGKB summary: tamoxifen pathway, pharmacokinetics (2013) (90)
PharmGKB summary: fluoropyrimidine pathways. (2010) (89)
PharmGKB summary: very important pharmacogene information for UGT1A1 (2014) (89)
WebFEATURE: an interactive web tool for identifying and visualizing functional sites on macromolecular structures (2003) (88)
Very important pharmacogene summary ADRB2 (2010) (88)
Platelet aggregation pathway. (2011) (87)
Clopidogrel: A Case for Indication‐Specific Pharmacogenetics (2012) (85)
PharmGKB summary: caffeine pathway (2012) (84)
PharmGKB summary: very important pharmacogene information for CYP1A2 (2012) (84)
Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC) (2016) (80)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens (2014) (79)
Thiopurine pathway. (2010) (74)
Selective serotonin reuptake inhibitors pathway. (2009) (72)
PharmGKB summary: tramadol pathway. (2014) (71)
Clinically Available Pharmacogenomics Tests (2009) (70)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Update (2020) (65)
Evidence and resources to implement pharmacogenetic knowledge for precision medicine. (2016) (65)
Review and Consensus on Pharmacogenomic Testing in Psychiatry (2020) (65)
PharmGKB summary: carbamazepine pathway (2011) (64)
Pacific symposium on biocomputing 2006 (2005) (63)
Automating Data Acquisition into Ontologies from Pharmacogenetics Relational Data Sources Using Declarative Object Definitions and XML (2001) (63)
PharmGKB summary: very important pharmacogene information for CYP2B6 (2010) (59)
Standardized biogeographic grouping system for annotating populations in pharmacogenetic research (2018) (59)
PharmGKB summary: phenytoin pathway (2012) (58)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (2014) (58)
PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. (2005) (57)
Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. (2014) (56)
PharmGKB very important pharmacogene: SLCO1B1. (2010) (55)
Pharmacogenetics at scale: An analysis of the UK Biobank (2020) (54)
PharmGKB summary: gemcitabine pathway (2014) (54)
PharmGKB summary: mycophenolic acid pathway (2014) (53)
PharmGKB summary: venlafaxine pathway (2014) (52)
Application of Information Technology: A Statistical Approach to Scanning the Biomedical Literature for Pharmacogenetics Knowledge (2004) (51)
Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. (2018) (51)
Very important pharmacogene summary for VDR (2012) (49)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes (2019) (48)
Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients. (2019) (47)
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms (2022) (47)
PharmGKB summary: citalopram pharmacokinetics pathway (2011) (47)
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update (2022) (46)
Improving data and knowledge management to better integrate health care and research (2013) (45)
PharmVar GeneFocus: CYP2C19 (2020) (43)
Pathway analysis of genome-wide data improves warfarin dose prediction (2013) (43)
Platinum pathway. (2009) (43)
PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics (2017) (43)
PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single‐drug pharmacogenetics (2008) (42)
Pharmacogene Variation Consortium Gene Introduction: NUDT15 (2018) (42)
Very important pharmacogene summary: thiopurine S-methyltransferase. (2010) (41)
Pharmacogenomics Clinical Annotation Tool (PharmCAT) (2019) (41)
ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). (2022) (40)
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. (2015) (40)
PharmGKB: An Integrated Resource of Pharmacogenomic Data and Knowledge (2008) (39)
Bisphosphonates pathway. (2011) (39)
PharmGKB summary: methylene blue pathway (2013) (37)
Ontology Development for a Pharmacogenetics Knowledge Base (2001) (37)
Etoposide pathway. (2009) (36)
PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics (2014) (36)
Microenvironment analysis and identification of magnesium binding sites in RNA. (2003) (36)
Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT‐RNR1 Genotype (2021) (36)
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6 (2012) (36)
Working toward precision medicine: Predicting phenotypes from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges (2017) (36)
Consortium ( CPIC ) guidelines for cytochrome P 450-2 C 19 ( CYP 2 C 19 ) genotype and clopidogrel therapy (2011) (35)
PharmCAT: A Pharmacogenomics Clinical Annotation Tool (2017) (35)
PharmGKB summary: very important pharmacogene information for G6PD (2012) (34)
Using ODIN for a PharmGKB revalidation experiment (2012) (33)
The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response (2016) (33)
PharmGKB summary: clozapine pathway, pharmacokinetics (2018) (32)
PharmVar and the Landscape of Pharmacogenetic Resources (2019) (31)
Expanding evidence leads to new pharmacogenomics payer coverage (2021) (30)
PharmGKB summary: Efavirenz pathway, pharmacokinetics (2015) (30)
The ACCOuNT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans (2019) (29)
Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder (2018) (28)
The PharmGKB: integration, aggregation, and annotation of pharmacogenomic data and knowledge (2007) (28)
PharmGKB summary: isoniazid pathway, pharmacokinetics (2016) (28)
Proceedings of the Pacific Symposium on Biocomputing '96. Hawaii, USA, 3-6 January 1996. (1996) (27)
Genome-wide association study of warfarin maintenance dose in a Brazilian sample. (2015) (27)
New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision Medicine (2017) (27)
PharmGKB summary: sorafenib pathways (2017) (27)
PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics (2015) (25)
Finding Relevant Biomolecular Features (1993) (25)
Correction to: ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG) (2021) (24)
SLC19A1 pharmacogenomics summary (2010) (24)
Sequence to Medical Phenotypes: A Framework for Interpretation of Human Whole Genome DNA Sequence Data (2015) (24)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy (2018) (23)
Vascular endothelial growth factor pathway. (2010) (23)
Preemptive Clinical Pharmacogenetics Implementation: Current programs in five United States medical centers (2015) (23)
PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2. (2011) (23)
Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation (2021) (23)
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium (2020) (22)
Indexing pharmacogenetic knowledge on the World Wide Web. (2003) (22)
Genome‐wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC) (2017) (22)
Challenges in the Pharmacogenomic Annotation of Whole Genomes (2013) (22)
PharmGKB summary: very important pharmacogene information for SLC22A1 (2014) (22)
Taxane pathway. (2009) (21)
Very important pharmacogene summary: sulfotransferase 1A1. (2009) (21)
A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy (2020) (21)
Pharmacogenomics and big genomic data: from lab to clinic and back again. (2018) (20)
PharmGKB summary: very important pharmacogene information for CYP4F2 (2015) (20)
PharmGKB, an Integrated Resource of Pharmacogenomic Knowledge (2021) (19)
A functional analysis of disease-associated mutations in the androgen receptor gene. (2003) (19)
New feature: pathways and important genes from PharmGKB. (2009) (19)
PharmGKB summary: very important pharmacogene information for ABCG2 (2017) (18)
PharmVar GeneFocus: CYP2B6 (2021) (18)
The Education Potential of the Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB) (2007) (18)
PharmVar GeneFocus: CYP2C9 (2021) (18)
PharmGKB summary: voriconazole pathway, pharmacokinetics (2017) (18)
Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic? (2019) (18)
The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression (2019) (18)
PharmGKB summary: dopamine receptor D2. (2011) (17)
PharmGKB summary: very important pharmacogene information for MT-RNR1 (2016) (17)
Evidence synthesis and guideline development in genomic medicine: current status and future prospects (2014) (17)
Biomedical informatics training at Stanford in the 21st century (2007) (17)
PharmGKB summary: very important pharmacogene information for PTGS2 (2011) (16)
Consortium : CPIC Guideline for SLCO 1 B 1 and Simvastatin-Induced Myopathy (2012) (16)
PharmGKB summary: very important pharmacogene information for human leukocyte antigen B (2015) (16)
Pharmacogenetic information in Swiss drug labels – a systematic analysis (2020) (15)
PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor (2013) (15)
Interpreting the CYP2D6 Results From the International Tamoxifen Pharmacogenetics Consortium (2014) (15)
PharmGKB summary: oxycodone pathway, pharmacokinetics (2018) (15)
Clinical evaluation incorporating a personal genome (2010) (14)
PharmGKB summary: very important pharmacogene information for GSTT1 (2012) (14)
Clinical Implementation of Pharmacogenetics: More than One Gene at a Time (2013) (14)
PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics (2014) (14)
PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics (2020) (13)
CORRIGENDUM: Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics (2017) (13)
PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics (2017) (13)
PATH-SCAN: A Reporting Tool for Identifying Clinically Actionable Variants (2013) (13)
PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme (2010) (13)
PharmGKB summary: sertraline pathway, pharmacokinetics (2019) (12)
PharmGKB summary: zidovudine pathway. (2012) (12)
PharmGKB: very important pharmacogene--HMGCR. (2011) (11)
PGxMine: Text mining for curation of PharmGKB (2019) (11)
KCNH2 pharmacogenomics summary. (2010) (11)
Integrating large-scale genotype and phenotype data. (2006) (11)
PharmGKB summary: clobazam pathway, pharmacokinetics (2018) (10)
Pathway-based Approaches to Pharmacogenomics (2007) (10)
PharmGKB very important pharmacogene : SLCO 1 B 1 (2012) (10)
PharmGKB summary: very important pharmacogene information for RYR1 (2016) (10)
DNATwist: A Web‐Based Tool for Teaching Middle and High School Students About Pharmacogenomics (2010) (10)
PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics (2019) (9)
Population‐specific single‐nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans (2016) (9)
An “Omics” view of drug development (2004) (9)
Essential Characteristics of Pharmacogenomics Study Publications (2018) (9)
Antiestrogen pathway (aromatase inhibitor). (2009) (9)
The Case for Pharmacogenetics‐Guided Prescribing of Codeine in Children (2018) (8)
Response to “Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole” (2018) (8)
PharmGKB summary: pazopanib pathway, pharmacokinetics (2017) (8)
PharmVar GeneFocus: SLCO1B1 (2022) (7)
Enabling the Curation of Your Pharmacogenetic Study (2015) (7)
PharmGKB summary: abacavir pathway (2014) (6)
Response to “Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped” ‐ The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole (2017) (6)
Biocomputing '97 - Proceedings of the Pacific Symposium (1996) (6)
Considerations for pharmacogenomic testing in a health system (2019) (6)
Pharmacogenetics: Call to Action (2011) (6)
Verifying nomenclature of DNA variants in submitted manuscripts: Guidance for journals (2020) (6)
Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG). (2022) (5)
Abstract 15518: Novel SNPs Associated with Warfarin Dose in a Large Multicenter Cohort of African Americans: Genome Wide Association Study and Replication Results (2011) (5)
An XML‐based interchange format for genotype–phenotype data (2008) (5)
PharmGKB summary: very important pharmacogene information for CFTR (2015) (5)
PharmGKB summary: very important pharmacogene information for CACNA1S (2019) (5)
PharmVar GeneFocus: CYP3A5 (2022) (5)
PharmGKB summary: diuretics pathway, pharmacodynamics (2013) (4)
A Resource to Acquire and Summarize Pharmacogenetics Knowledge in the Literature (2004) (4)
PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics (2018) (4)
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for thiopurine methyltransferase (TPMT) genotype and thiopurine dosing (2011) (4)
Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype (2022) (4)
PharmGKB Tutorial for Pharmacogenomics of Drugs Potentially Used in the Context of COVID‐19 (2020) (3)
Pharmacogenomics in dermatology: tools for understanding gene-drug associations. (2019) (3)
How to improve data and knowledge management to better integrate healthcare and research (2013) (3)
PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics (2019) (3)
Proceedings of the Pacific Symposium on Biocomputing '97. Maui, Hawaii, USA, 6-9 January 1997. (1997) (2)
Response to: Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. (2020) (2)
Pacific Symposium on Biocomputing '99, World Scientific, New Jersey; Pacific Symposium on Biocomputing '00, World Scientific, New Jersey; Pacific Symposium on Biocomputing '01, World Scientific, New Jersey (2003) (2)
Governmental and Academic Efforts to Advance the Field of Pharmacogenomics (2013) (2)
Pharmacogenomics: The relevance of emerging genotyping technologies. (2006) (2)
An Investigation of the Knowledge Overlap between Pharmacogenomics and Disease Genetics (2021) (2)
Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population (2022) (2)
Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention (2020) (2)
Pacific symposium on biocomputing `97: Proceedings (1996) (2)
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Term Standardization for Clinical Pharmacogenetic Test Results: Alleles and Phenotypes (2016) (2)
Re: CYP2D6 genotyping and the use of tamoxifen in breast cancer. (2014) (1)
Consortium ( CPIC ) guideline for thiopurine dosing based on TPMT and NUDT 15 genotypes : 2018 update (2018) (1)
Novel Disease–Drug Database Demonstrating Applicability for Pharmacogenomic‐Based Prescribing (2016) (1)
A personalized and automated dbSNP surveillance system (2003) (1)
PharmGKB : A Resource to Link Genotype and Phenotype in Pharmacogenetics (2005) (1)
Genotype-guided dosing of vitamin K antagonists. (2014) (1)
PharmGKB summary: heparin-induced thrombocytopenia pathway, adverse drug reaction (2022) (1)
Pacific Symposium on Biocomputing 2004: Hawaii, USA 6-10 January 2004 (2004) (1)
Biocomputing 2006, Proceedings of the Pacific Symposium, Maui, Hawaii, USA, 3-7 January 2006 (2006) (1)
Biocomputing 2007, Proceedings of the Pacific Symposium, Maui, Hawaii, USA, 3-7 January 2007 (2007) (0)
Biocomputing 2008, Proceedings of the Pacific Symposium, Kohala Coast, Hawaii, USA, 4-8 January 2008 (2008) (0)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. (2023) (0)
Year : 2012 Using ODIN for a PharmGKB revalidation experiment (2017) (0)
Special Paper - Introduction (2003) (0)
A Twentieth Anniversary Tribute to PSB (2014) (0)
Guidelines for CYP 2 C 9 and VKORC 1 Genotypes and Warfarin Dosing – ONLINE SUPPLEMENT (2011) (0)
Biocomputing 2004, Proceedings of the Pacific Symposium, Hawaii, USA, 6-10 January 2004 (2004) (0)
CL-01 Translation of Clinical Proteomics : Opportunities and Challenges (2013) (0)
Pharmacogenetics Implementation: Current Programs in Five US Medical (2015) (0)
PharmGKB summary: acyclovir/ganciclovir pathway (2022) (0)
<scp>PharmVar GeneFocus</scp> : <scp> <i>SLCO1B1</i> </scp> (2022) (0)
PharmGED : Pharmacogenetic effect database. Commentary (2007) (0)
FRONT MATTER (2018) (0)
Preface (2019) (0)
Pathway analysis of genome-wide data improves warfarin dose prediction (2013) (0)
PharmGKB summary: peginterferon-&agr; pathway (2015) (0)
School of Medicine (2008) (0)
Expression Quantitative Trait Loci Analysis of Stable Warfarin Dose Identifies Novel Associations : Finding Signal within the Noise (2013) (0)
Protein Domain-Centric Approach to Study of Cancer Somatic Mutations . 10 : 10 – 10 : 30 Coffee Break (2012) (0)
Pharmacogenomic Knowledge and Discovery (2011) (0)
An Introduction to PharmGKB: A Research Tool for Pharmacogenomics (2007) (0)
FRONT MATTER (2019) (0)
E ﬀ ect of CYP3A4 *22 and PPAR- α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention (2020) (0)
FRONT MATTER (2020) (0)
Systems Pharmacogenomics-Bridging the Gap (2012) (0)
How to Run the Pharmacogenomics Clinical Annotation Tool (PharmCAT) (2022) (0)
Chapter 39. Pharmacogenetics/Pharmacogenomics (2008) (0)
Biocomputing 2020 (2019) (0)
Considerations for pharmacogenomic testing in a health system (2019) (0)
Principles of Pharmacogenetics and Pharmacogenomics: PharmGKB, a Centralized Resource for Pharmacogenomic Knowledge and Discovery (2012) (0)
Biocomputing 2021: Proceedings of the Pacific Symposium, Kohala Coast, Hawaii, USA, January 3-7, 2021 (2020) (0)
Chapter 14 – PharmGKB: The Pharmacogenomics Knowledgebase (2014) (0)

This paper list is powered by the following services:

Other Resources About Teri Klein

en.wikipedia.org

What Schools Are Affiliated With Teri Klein?

Teri Klein is affiliated with the following schools: